InflaRx N.V. - Common Stock (IFRX)
Frequently Asked Questions About InflaRx N.V. - Common Stock (IFRX)
How does InflaRx ensure compliance with regulatory standards?
InflaRx adheres to stringent regulatory frameworks and guidelines set forth by agencies such as the FDA and EMA. This includes conducting preclinical studies and clinical trials in accordance with Good Clinical Practice (GCP) and ensuring that all product development activities comply with regulatory requirements.
How does InflaRx maintain its financial sustainability?
InflaRx maintains financial sustainability through a combination of public offerings, strategic partnerships, and grants. The company continuously seeks to enhance its capital structure to fund ongoing research and development, clinical trials, and operational activities critical to its goals.
How often does InflaRx communicate with investors?
InflaRx maintains regular communication with investors through quarterly earnings calls, press releases, and investor presentations. The company aims to keep stakeholders informed about its progress, financial performance, and future strategic directions.
On which stock exchange is InflaRx listed?
InflaRx N.V. is listed on the Nasdaq stock exchange under the ticker symbol IFRX. The company went public in 2018, allowing it to raise capital for further development of its drug pipeline.
What are the company's goals for clinical trials?
InflaRx aims to advance its product candidates through rigorous clinical trials to demonstrate safety and efficacy in treating inflammatory diseases. The company's goals include obtaining regulatory approval for its therapies and bringing innovative treatments to market for patients with high unmet medical need.
What challenges does InflaRx face in the biopharmaceutical industry?
InflaRx faces challenges typical of the biopharmaceutical industry, including regulatory hurdles, the complexity of clinical trials, competition from existing therapies, and the need for substantial funding. Navigating these challenges is essential for the successful development and commercialization of its drug candidates.
What collaborations or partnerships does InflaRx have?
InflaRx engages in strategic collaborations and partnerships with academic institutions, research organizations, and other biotech firms to enhance its drug development capabilities. These partnerships often aim to leverage complementary expertise and resources to accelerate advancements in treatment options.
What does InflaRx N.V. do?
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of serious inflammatory and autoimmune diseases. The company's primary focus is on developing inhibitors of the complement system to address unmet medical needs in various diseases.
What future prospects are there for InflaRx?
InflaRx is optimistic about its future prospects, with ongoing clinical trials that could lead to successful drug approvals. The company's commitment to innovation, coupled with a focus on unmet medical needs in inflammatory diseases, positions it well to become a leader in the biopharmaceutical space.
What is IFX-1 used for?
IFX-1 is an investigational drug that targets complement factor C5a, and it is primarily being studied for its potential to treat conditions such as hidradenitis suppurativa and complications arising from severe COVID-19. The drug aims to alleviate inflammation and improve patient outcomes in these challenging diseases.
What is InflaRx's approach to patient engagement?
InflaRx values patient engagement as an integral part of its development process. The company actively seeks patient feedback and involvement in clinical trials to better understand their needs and experiences, ensuring that the therapies developed are aligned with patient expectations and real-world outcomes.
What is the company's approach to intellectual property?
InflaRx places significant emphasis on protecting its intellectual property portfolio. The company actively seeks patents for its novel molecules and therapeutic candidates, which helps to secure its innovations and maintain a competitive edge in the biopharmaceutical market.
What is the company's mission statement?
InflaRx's mission is to improve the lives of patients suffering from serious inflammatory and autoimmune diseases through the development of groundbreaking therapeutics. The company is dedicated to addressing critical unmet medical needs and enhancing patient care through innovative solutions.
What is the main product pipeline of InflaRx?
InflaRx's main product pipeline includes IFX-1, an anti-complement factor C5a monoclonal antibody, which is being developed for the treatment of several inflammatory diseases, including hidradenitis suppurativa, and more broadly, for indications in severe COVID-19. The company is also investigating other therapies targeting the complement system.
What is the significance of complement inhibition in InflaRx's research?
Complement inhibition plays a crucial role in InflaRx's research because it targets a key component of the immune system involved in inflammatory processes. Dysregulation of the complement system is associated with various diseases, making this therapeutic approach potentially transformative for treating patients with serious conditions.
What is the significance of the complement system in disease?
The complement system is a part of the immune response that plays a critical role in inflammation and pathogen clearance. Dysregulation of this system is linked to various diseases, offering therapeutic targets for treating conditions like autoimmune disorders and severe infections, which is the focus of InflaRx's research.
What recent milestones has InflaRx achieved?
InflaRx has achieved several key milestones, including successful completion of clinical trial phases for IFX-1, granting of patents for its technologies, and expanding its collaborations with research institutions. These accomplishments are paving the way for further development and commercialization of its therapeutic candidates.
Where is InflaRx N.V. headquartered?
InflaRx N.V. is headquartered in Jena, Germany. The location facilitates its collaboration with leading research institutions and enables access to a network of biotechnology innovation in Europe.
Who are the key executives at InflaRx?
InflaRx's leadership team includes experienced professionals from the pharmaceutical and biotech industries. This includes the CEO, Prof. Niels C. R. W. H. Sönksen, who brings extensive experience in drug development, along with a team of experts focusing on clinical and regulatory strategies.
What is the current price of InflaRx N.V. - Common Stock?
The current price of InflaRx N.V. - Common Stock is 2.580
When was InflaRx N.V. - Common Stock last traded?
The last trade of InflaRx N.V. - Common Stock was at 4:00 pm EDT on May 8th, 2026
What is the market capitalization of InflaRx N.V. - Common Stock?
The market capitalization of InflaRx N.V. - Common Stock is 114.05M
How many shares of InflaRx N.V. - Common Stock are outstanding?
InflaRx N.V. - Common Stock has 44.20M shares outstanding.